Namodenoson

N/A

Report date: 2026/01/21 16:37:08
NME

Base Information

Drug NameNamodenoson
Drug Alias NameCl-IB-MECACF-102
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAdenosine A3 receptor agonists
TargetsAdenosine A3 receptor
Therapy Area/IndicationsLiver CirrhosisMetabolic Dysfunction-Associated Steatotic Liver DiseasePancreatic Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBosnia and HerzegovinaBulgariaUnited States +[10] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesNational Institutes Of Health
China Registration ClassN/A

Develop Information

Active CompaniesChina Medical System Holdings LtdCan-Fite Biopharma Ltd
Inactive CompaniesN/A
Active IndicationsLiver CirrhosisMetabolic Dysfunction-Associated Steatotic Liver DiseasePancreatic Neoplasms +[4] 
Inactive IndicationsHepatitis C, Chronic

Other Information

ATC CodeN/A
Related LinksDrugBankKEGG